【StarPharm X64 交流专区】斯达制药 STAR PHARMACEUTICAL LIMITED

icy97

CORPORATE PROFILE
* Extracted from Annual Report 2012
STAR Pharmaceutical (the "Company" or the "Group") was established in 2005 and was listed on the SGX mainboard in February 2006. The Company specialises in the manufacture and sales of both western and TCM-formulated prescription drugs and has a manufacturing facility based in Qionghai City, Hainan Province of China, and a JV research institute with Peking University.

The Group's broad range of pharmaceutical products include antibiotics, cerebrovascular drugs and cardiovascular drugs, and other specialised drugs manufactured inhouse in various dosages and administration forms from powder injections, lyophilized powder injections, liquid injections to tablets, capsules and granules.

The Group has a well-established, extensive distribution network which supports its sales in the growing China market. These include approximately 398 distributors to hospitals, clinics and pharmacies. The Group also operates 32 liaison offices established in major cities and provinces in the PRC.

R&D is a cornerstone of the Group's mission and growth strategy. The Group has an inhouse R&D team with its R&D capabilities further sharpened through its 2006 acquisition of 60% equity stake in Beida Shijia Technology Development Co., Ltd ("Beida Shijia"), a leading TCMformulated drug research institute with partnership ties with Peking University.

The Group enjoys a reputable standing in the pharmaceutical industry, as a State Level High Tech Enterprise. Over the years, it has received numerous industry awards which recognise the innovative, quality products that the Group brings to the pharmaceutical market.

公司官网：http://starpharm.listedcompany.com/

Name of Announcer *	STAR PHARMACEUTICAL LIMITED
Company Registration No.	200500429W
Announcement submitted on behalf of	STAR PHARMACEUTICAL LIMITED
Announcement is submitted with respect to *	STAR PHARMACEUTICAL LIMITED
Announcement is submitted by *	Xu Zhi Bin
Designation *	Executive Chairman
Date & Time of Broadcast	12-Aug-2013 18:35:57
Announcement No.	00177

>> ANNOUNCEMENT DETAILS

The details of the announcement start here ...

For the Financial Period Ended *	30-06-2013
Description	Please see attached.

Attachments

STAR_2Q13_12082013.pdf

icy97

文： 2014年03月13日 每日头条
http://www.sharesinv.com/zh/articles/45372/

斯达制药(Star Pharmaceutical)已同意脱售其在北京制药公司Beijing Shijia Jiu Sheng Yuan Pharmaceutical Technology(SJYP)的14%股权。公司也建议以4,000万人民币脱售其在北大世佳科技开发及SJYP的80%和46%股权。公司预期将从中取得2,800万人民币的收益。两家公司从事制药及中药研发业务，把它们脱售是因为它们现已不符合公司的策略和拓展方向。公司将把焦点放在核心的西药业务上。